• BridgeBio published medical research presentation reporting a post hoc subgroup analysis from Phase 3 ATTRibute-CM evaluating acoramidis impact on NT-proBNP through Month 30 versus placebo in ATTR-CM.
• Acoramidis blunted NT-proBNP rise by about 50% across pre-specified subgroups, including advanced disease; treatment effects favored acoramidis in all subgroups assessed (all p<0.001).
• Month 30 analysis included 595 randomized participants; 45% of acoramidis recipients with paired data had net NT-proBNP decrease versus 9% on placebo.
• In participants without concomitant tafamidis, median NT-proBNP change at Month 30 was 86 pg/mL for acoramidis alone versus 1,135 pg/mL for placebo alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.